The UK becoming the first country in Europe to approve orforglipron is a massive win for people struggling with obesity. This once-daily pill — no food or water restrictions, proven to deliver nearly 12.5% weight loss in trials — finally gives patients a flexible, accessible option. Expanding treatment choices is exactly how modern medicine should work, and this approval is a step in the right direction.
Obesity pills like orforglipron deliver real weight loss but also bring real trade-offs — more side effects, lean muscle loss and no proven quality-of-life gains at one year. These drugs don't fix the root causes driving obesity rates higher every decade, and long-term safety data is still thin. Handing out pills without addressing diet, environment and lifestyle is treating symptoms, not the actual problem.
© 2026 Improve the News Foundation.
All rights reserved.
Version 7.4.1